News & Events about Werewolf Therapeutics Inc.
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the Company or Werewolf) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research Online First ...
WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the Company or Werewolf) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of ...
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in Patients with Advanced or Metastatic Solid Tumors orNon-Hodgkin Lymphoma Second clinical stage program ...
Werewolf Therapeutics, Inc. (NASDAQ:HOWL Get Rating) Director Ra Capital Management, L.P. purchased 1,853,000 shares of the firms stock in a transaction on Friday, January 6th. The shares were purchased at an average cost of $2.21 per share, with a total value of $4,095,130.00. ...
Thinking about buying stock in Biora Therapeutics, AMC Entertainment, Werewolf Therapeutics, Broadwind, or BioNano Genomics? Thinking about buying stock in Biora Therapeutics, AMC Entertainment, Werewolf Therapeutics, Broadwind, or BioNano Genomics? PR Newswire NEW YORK, Jan. 11, 2023 NEW YORK...